GlassScriptPhysician profile
Sajjad Nasir
NPI 1518196807
$6,686.37
in general payments reported to CMS, 2019-2025
20 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.99 · 2021: $14.70 · 2022: $455 · 2023: $5,088 · 2024: $780 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $2,294 · Travel and Lodging: $1,073 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $2,294.02 |
| Travel and Lodging | $1,072.53 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,119.60 | 2023-2024 | |
| Celgene Corporation | $1,615.57 | 2023-2024 | Zeposia |
| Abbvie INC. | $455.30 | 2021-2025 | |
| Pfizer INC. | $214.76 | 2023-2025 | |
| Abbott Laboratories | $209.33 | 2022-2024 | Infinity |
| Lilly USA, LLC | $207.04 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $202.66 | 2022-2024 | Ajovy, Austedo |
| Acadia Pharmaceuticals INC | $132.10 | 2022-2024 | Nuplazid |
| Ge Healthcare | $90.64 | 2022-2025 | |
| Emd Serono, INC. | $85.98 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $81.79 | 2024-2025 | |
| Argenx US, INC. | $71.73 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $53.78 | 2024-2025 | |
| Lundbeck LLC | $29.07 | 2023 | Vyepti |
| Janssen Pharmaceuticals, INC | $28.28 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.83 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.09 | 2022 | |
| Biogen, INC. | $19.06 | 2025 | Leqembi |
| Amneal Pharmaceuticals LLC | $15.62 | 2025 | Ongentys |
| Amgen INC. | $15.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.